350TiP A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)

Authors :: Andrew Foxley
Sacha J Howell
P. Ni
X. C. Hu
Mafalda Oliveira
M. Toi
H. Gomez
Komal Jhaveri
Hope S. Rugo
E. De Bruin
C.M.A.A. Orbegoso
N. Turner
Gaia Schiavon
S. Loibl
Source :: Annals of Oncology. 31:S388-S389
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Fulvestrant
business.industry
Hematology
medicine.disease
Placebo
Breast cancer
Internal medicine
Medicine
In patient
business
medicine.drug

Full Text Access

Tools